Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection

Clinics in Dermatology

Volumn 18, Issue 4, 2000, Pages 485-489

  Heller, Howard M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; FOSCARNET; HYPERICIN; NEVIRAPINE; PYRIMETHAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFADOXINE; SULFONAMIDE; TRIMETHOPRIM; ZALCITABINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RASH; REVIEW; SKIN MANIFESTATION;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; DRUG ERUPTIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMAN;

EID: 0033825122     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00144-3     Document Type: Review

References (30)

1. Coopman S.A., Johnson R.A., Platt R., et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 328:1993;1670-1674.
2. Fisher C.A., McPoland P.R. Azidothymidine-induced nail pigmentation. Cutis. 43:1989;552-554.
3. Greenberg R.G., Berger T.G. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol. 22:1990;327-330.
4. Rahav G., Maayan S. Nail pigmentation associated with zidovudine A review and report of a case . Scand J Infect Dis. 24:1992;557-561.
5. Glaser D.A., Remlinger K. Blue nails and acquired immunodeficiency syndrome Not always associated with azidothymidine use . Cutis. 57:1996;243-244.
6. Roudier C., Caumes E., Rogeaux O., et al. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch Dermatol. 130:1994;1383-1386.
7. Hughes W.T., LaFon S.W., Scott J.D., et al. Adverse events associated with trimethoprim-sulfamethoxazole during the treatment of Pneumocystis carinii pneumonia. J Infect Dis. 171:1995;1295-1301.
8. Carr A., Swanson C., Penny R., et al. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis. 167:1993;180-185.
9. Caumes E., Roudier C., Rogeaux O., et al. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia. Clin Infect Dis. 18:1994;319-323.
10. Walmsley S., Levinton C., Brunton J., et al. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol. 8:1995;348-357.
11. Gill H.J., Maggs J.L., Madden S., et al. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br J Clin Pharmacol. 42:1996;347-353.
12. Carr A., Tindall B., Penny R., et al. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol. 94:1993;21-25.
13. Rieder M.J., Krause R., Bird I.A., et al. Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J Acuir Immune Defic Syndr Hum Retrovirol. 8:1995;134-140.
14. Rieder M.J., Krause R., Bird I.A. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology. 95:1995;141-146.
15. Smith C.L., Brown I., Torraca B.M. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis. 25:1997;1477-1478.
16. Lee B., Wong D., Benowitz N.L., et al. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharm Ther. 53:1993;529-535.
17. Rose E.W., McCloskey W.W. Glutathione in hypersensitivity to trimethoprim/sulfamethoxazole in patients with HIV infection. Ann Pharmacother. 32:1998;381-383.
18. Akerlund B., Tynell E., Bratt G., et al. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. J Infect. 35:1997;143-147.
19. Gruchalla R.S., Pesenko R.D., Do T.T., et al. Sulfonamide-induced reactions in desensitized patients with AIDS - the role of covalent protein haptenation by sulfamethoxazole. J Allergy Clin Immunol. 101:1998;371-378.
20. Veenstra J., Veugelers P.J., Keet I.P.M., et al. Rapid disease progression in HIV-1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole. Clin Infect Dis. 24:1997;936-941.
21. Leeder S., Nakhooda A., Spielberg S.P., et al. Cellular toxicity of sulfamethoxazole reactive metabolites. Inhibition of natural killer activity in human peripheral blood mononuclear cells. Biochem Pharmacol. 41:1991;75-83.
22. Rieder M.J., Sisson E., Bird L.A., Almawy W.Y. Suppression of T-lymphocyte proliferation by sulphonamide hydroxylamines. Int J Immunopharmacol. 7:1992;1175-1180.
23. Guo R., Thormann W., Lauterberg B. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Chin Med J. 109:1996;933-936.
24. Rousseau F., Pueyo S., Morlat P., et al. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. Clin Infect Dis. 24:1997;396-402.
25. May T, Beuscart C, Reynes J, et al. Cutaneous hypersensitivity to sulfamethoxazole-trimethoprim (SMZ-TMP) in HIV-infected patients: A major risk factor for developing toxoplasmic encephalitis (TE). In: Programs and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. (abstract I-177) Washington, DC: American Society for Microbiology, 1994;169.
26. Hawken M., Nunn P., Gathua S., et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet. 342:1993;332-337.
27. Fitzgerald E., Goldman H.M., Miller W.G., et al. A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet-induced penile ulceration. Arch Dermatol. 131:1995;1449.
28. Evans L.M., Grossman M.E. Foscarnet-induced penile ulcer. J Am Acad Dermatol. 27:1992;124-126.
29. Gross A.S., Dretler R.H. Foscarnet-induced penile ulcer in an uncircumcised patient with AIDS. Clin Infect Dis. 17:1993;1076-1077.
30. Lacey H.B., Ness A., Mandal B.K. Vulval ulceration associated with foscarnet. Genitourin Med. 68:1992;182.